AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21724623
Drug: Pegnivacogin 1
RxNorm normalized name: Pegnivacogin
DrugBank: Pegnivacogin (DB06293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegnivacogin 1 mg/kg
Trial: 21724623
Drug: Control agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control agent (anivamersen)
Trial: 19633475
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/d alone (arm A)
Trial: 19633475
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/d in combination with bortezomib 1.6 mg/m2 (arm B)
Trial: 19633475
Drug: Erlotinib +/-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib +/- bortezomib in patients with epidermal growth factor receptor mutations
Trial: 16752169
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg or 80 mg daily
Trial: 9223713
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (isotonic saline)
Trial: 7963104
Drug: combination thrombolytic
RxNorm normalized name: THROMBOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination thrombolytic therapy
Trial: 30269747
Drug: Upright position,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upright position, 60 mg prasugrel
Trial: 30269747
Drug: Supine position,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supine position, 60 mg prasugrel
Trial: 18608053
Drug: Intravaginal gel
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal gel (microbicide)
Trial: 11942734
Drug: Red Orange
RxNorm normalized name: TITANIUM DIOXIDE 2.32 g in 25 g CUTANEOUS CREAM [RED ORANGE JELLY BB SPF20 PA PLUS PLUS NO.1]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red Orange Complex (ROC) 50 mg/d, orally
Trial: 10512958
Drug: Freehand tooth
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freehand tooth preparations
Trial: 7719358
Drug: Moxisylyte hydrochloride
RxNorm normalized name: Moxisylyte hydrochloride
DrugBank: Moxisylyte (DB09205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxisylyte hydrochloride (0.5 mg/kg)
Trial: 2332986
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of chlorambucil and prednisolone
Trial: 204058
Drug: Gaviscon tablets
RxNorm normalized name: Gaviscon
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaviscon tablets
Trial: 28587616
Drug: Mirococept 10
RxNorm normalized name: Mirococept
DrugBank: Mirococept (DB06492)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirococept 10 mg
Trial: 28587616
Drug: Mirococept (5-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirococept (5-25 mg, dose allocation based on interim analysis)
Trial: 22652183
Drug: Pixantrone dimaleate
RxNorm normalized name: Pixantrone dimaleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pixantrone dimaleate (85 mg/m² intravenously on days 1, 8, and 15 of a 28-day cycle, for up to six cycles)
Trial: 22652183
Drug: Comparator (vinorelbine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator (vinorelbine, oxaliplatin, ifosfamide, etoposide, mitoxantrone, or gemcitabine at prespecified standard doses and schedules)
Trial: 18563435
Drug: DHA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (2 g/day) + EPA (3 g/day)
Trial: 15804658
Drug: Ototopical treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ototopical treatments for chronic suppurative otitis media; details on dosage and duration not available.
Trial: 11872916
Drug: Statin agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin agents
Trial: 11872916
Drug: Traditional antithrombotic
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional antithrombotic agents
Trial: 10353432
Drug: Desipramine 100
RxNorm normalized name: desipramine 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine 100 mg
Trial: 1384397
Drug: Hydromorphone alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone alone by bolus administration
Trial: 1384397
Drug: Hydromorphone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone with a continuous (basal) infusion
Trial: 1384397
Drug: Hydromorphone in
RxNorm normalized name: hydromorphone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone in combination with 0.08% bupivacaine by bolus administration
Trial: 1384397
Drug: Hydromorphone and
RxNorm normalized name: hydromorphone and naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone and bupivacaine, with a concurrent infusion of both drugs
Trial: 3893680
Drug: MDF +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MDF + Misonidazole (1.25 g/m2 three times weekly for the first 3 weeks)
Trial: 30032883
Drug: Transport on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transport on a gurney without premedication (Group G)
Trial: 30032883
Drug: Transport on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transport on a gurney with oral midazolam 0.5 mg kg-1 (Group M)
Trial: 19526249
Drug: Praneem tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praneem tablet
Trial: 15451335
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral misoprostol (600 microg)
Trial: 15451335
Drug: Repeated dose
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated dose of oral misoprostol (1200 microg total, given as 600 microg every 4 hours)
Trial: 15451335
Drug: Repeated dose
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated dose of oral misoprostol (1200 microg total)
Trial: 11352373
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) - 2 hour session
Trial: 9671370
Drug: 5 ng/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ng/kg/min PGE1 and 6 IU/kg/hr heparin
Trial: 9671370
Drug: 20 ng/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ng/kg/min PGE1 and 6 IU/kg/hr heparin
Trial: 7743685
Drug: Enoximone (bolus-infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (bolus-infusion of 0.5 mg/kg over 10 min followed by an infusion of 5 micrograms/kg/min up to 20 micrograms/kg/min)
Trial: 7743685
Drug: Epinephrine/nitroglycerin (infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine/nitroglycerin (infusion of 0.05 and 0.5 micrograms/kg/min, respectively, for 4 hours postoperatively)
Trial: 2201732
Drug: Zopiclone 7.5
RxNorm normalized name: zopiclone 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone 7.5 mg at bed time
Trial: 7282598
Drug: High plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High plasma vitamin C levels (16.28 +/- 3.75 mg/l) due to supplementation
Trial: 7282598
Drug: Low plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low plasma vitamin C levels (6.15 +/- 3.88 mg/l)
Trial: 31796486
Drug: Home treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home treatment (n=101)
Trial: 31796486
Drug: Hospital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital treatment (n=102)
Trial: 28100019
Drug: HVPG-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HVPG-guided therapy
Trial: 26520144
Drug: AC (adriamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC (adriamycin 60 mg/m(2), cyclophosphamide 600 mg/m(2)) followed by docetaxel 100 mg/m(2) with primary GCSF prophylaxis
Trial: 26520144
Drug: FEC (5‐fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC (5‐fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), cyclophosphamide 500 mg/m(2)) followed by docetaxel 75 mg/m(2)
Trial: 23640486
Drug: Hypolipidemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypolipidemic therapy (fenofibrate, niacin, diet, and exercise)
Trial: 22093195
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) comprising aspirin (100 mg), ramipril (2.5, 5, or 10 mg), and simvastatin (40 mg)
Trial: 22093195
Drug: Separate administration
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate administration of aspirin, ramipril, and simvastatin
Trial: 17710007
Drug: Khan Kinetic
RxNorm normalized name: Kineticream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Khan Kinetic Treatment (KKT)
Trial: 16163169
Drug: Increasing the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing the dose of radiotherapy or adding a brachytherapy boost
Trial: 11528196
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg vardenafil
Trial: 11528196
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of vardenafil (20 mg and 40 mg)
Trial: 9749589
Drug: Deprenyl (selegiline)
RxNorm normalized name: L-deprenyl-D2 C-11
DrugBank: L-deprenyl-D2 C-11 (DB12650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deprenyl (selegiline) 10 mg/day
Trial: 9749589
Drug: Open-label deprenyl
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label deprenyl treatment
Trial: 7810015
Drug: Budesonide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (400 microgrammes daily via Turbuhaler)
Trial: 6102896
Drug: Slow-release preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release preparations of Metoprolol
Trial: 6102896
Drug: Slow-release preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release preparations of Propranolol
Trial: 30760320
Drug: Umbilical therapy
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umbilical therapy with Lishui Xiaogu cataplasm plus red light irradiation along with conventional treatment
Trial: 30760320
Drug: Placebo cataplasm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cataplasm plus red light irradiation along with conventional treatment
Trial: 23663658
Drug: Bosentan (endothelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (endothelin receptor antagonist) administered for 14 weeks
Trial: 21832027
Drug: Vitamin D-fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D-fortified milk (mean intake of 3.7 μg/d)
Trial: 15223899
Drug: FTY720 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 0.25 mg
Trial: 15223899
Drug: FTY720 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 0.5 mg
Trial: 15223899
Drug: FTY720 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 1.0 mg
Trial: 17061999
Drug: FTY720 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 2.5 mg
Trial: 9569474
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of recombinant hepatitis B vaccine (10 micrograms or 20 micrograms of HBsAg per dose), administered 6 months apart
Trial: 9569474
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of vaccine given 2 years later
Trial: 31428894
Drug: Rikkunshito (RKT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rikkunshito (RKT) 7.5 g/day for 14 days
Trial: 28615257
Drug: Iron supplement
RxNorm normalized name: Iron supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplement (18 mg/d)
Trial: 23715625
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg
Trial: 20966119
Drug: New equations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New equations to estimate creatinine excretion rate (CER) with serum phosphorus
Trial: 20966119
Drug: New equations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New equations to estimate creatinine excretion rate (CER) without serum phosphorus
Trial: 20966119
Drug: Existing equations
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Existing equations to estimate creatinine excretion rate (CER)
Trial: 14551493
Drug: S/B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S/B vaccine groups
Trial: 8752186
Drug: Lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 mg twice daily
Trial: 8752186
Drug: Lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 40 mg twice daily
Trial: 1418102
Drug: Lovastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 80 mg twice daily
Trial: 1418102
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg twice daily
Trial: 1418102
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg twice daily
Trial: 1418102
Drug: Simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg twice daily
Trial: 29242283
Drug: BEZ235 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEZ235 400 mg twice daily
Trial: 27074806
Drug: 12-week multidisciplinary
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week multidisciplinary team care programme including a hand function treatment module
Trial: 25022113
Drug: Jin's three-needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jin's three-needle therapy (acupuncture)
Trial: 25022113
Drug: Desloratadine oral
RxNorm normalized name: desloratadine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine oral suspension (5 mg once a day for 20 days)
Trial: 22545252
Drug: Topical nystatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nystatin 4 times/day for 14 days
Trial: 11876709
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication treatment (1-week omeprazole-based triple therapy, followed by 7-week omeprazole)
Trial: 2184527
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet (RHZ), 5 tablets per day on weekdays for 100 treatment-days
Trial: 2184527
Drug: Four-drug regimen
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug regimen (RHZS) (streptomycin, rifampicin, isoniazid and pyrazinamide)
Trial: 376950
Drug: Treatment 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 1: Actinomycin-D (Act-D), 0.01 mg/kg IV, days 1-5; L-PAM, 4 mg PO, days 1-10 every six weeks
Trial: 376950
Drug: Treatment 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 2: Act-D, 0.01 mg/kg IV, days 1-5; L-PAM, 4 mg PO, days 1-10; Vincristine, 1 mg IV, days 1, 8, 15, 22, 29, 36, repeat every six weeks
Trial: 376950
Drug: Treatment 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 3: Act-D, 0.01 mg/kg IV, days 1-5; L-PAM, 4 mg PO, days 1-10; NSC-1026, 200 mg/kg IV, days 1-6
Trial: 376950
Drug: Treatment 4:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 4: Adriamycin, 0.4 mg/kg IV, days 1, 2, 3, 8, 9, 10, then 2XWK starting day 15 (max. 1,200 mg)
Trial: 28366181
Drug: ALA +
RxNorm normalized name: Alpha-Lipoic Acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA + quercetin (190 mg/d)
Trial: 28366181
Drug: ALA +
RxNorm normalized name: Alpha-Lipoic Acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA + placebo (3.3 g/d ALA)
Trial: 21760724
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg PO once daily for 5 days)
Trial: 21760724
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid (875/125 mg PO twice daily for 7 days)
Trial: 19843742
Drug: 64-MDCT with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 64-MDCT with oral and IV contrast media (Group 1)
Trial: 17426111
Drug: Triiodothyronine (T(3))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triiodothyronine (T(3)) infusion for 24 hours after surgery
Trial: 17426111
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion for 24 hours after surgery
Trial: 15553821
Drug: Shengxuening (SXN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shengxuening (SXN) 0.1 g, three times per day for 30 days
Trial: 15553821
Drug: Ferrous gluconate
RxNorm normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous gluconate 0.1 g, three times per day for 30 days
Trial: 7972781
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid (25 mg) and dipyridamole (200 mg) (ASAD) twice daily for 1 year
Trial: 7972781
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid (25 mg) and dipyridamole (200 mg) (ASAD)
Trial: 2685207
Drug: Nortriptyline (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (specific dosage and duration not mentioned)
Trial: 2685207
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving antidepressants at the time of assessment (specific treatment not mentioned)
Trial: 2685207
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment initiated after assessment (specific treatment not mentioned)
Trial: 22269198
Drug: Single session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single session filling without calcium hydroxide medication
Trial: 22269198
Drug: Calcium hydroxide-based
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide-based intracanal medication Calen®
Trial: 12631443
Drug: Oral antioxidative
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antioxidative treatment (Quatral) once daily for 16 weeks
Trial: 10698386
Drug: Adenosine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (12 mg intravenously)
Trial: 9329380
Drug: Estrogen (hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen (hormone replacement therapy)
Trial: 7870919
Drug: Alcohol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.5 g/l)
Trial: 7870919
Drug: Alcohol +
RxNorm normalized name: Benzyl alcohol + eucalyptus oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol + Diazepam (5 mg)
Trial: 23356032
Drug: Treatment lasting
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment lasting six months (intervention group)
Trial: 10393392
Drug: Oral isosorbide-5-mononitrate
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isosorbide-5-mononitrate (ISMN) 50 mg once daily
Trial: 8697554
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine alone (phase M)
Trial: 8697554
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of ketamine (1.0 mg) with morphine (phase M + K)
Trial: 1992660
Drug: DFO 40
RxNorm normalized name: DFO
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DFO 40 mg/kg
Trial: 1992660
Drug: DFO 80
RxNorm normalized name: DFO
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DFO 80 mg/kg
Trial: 1992660
Drug: DFO (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFO (both doses)
Trial: 1992660
Drug: DFO (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFO (higher doses)
Trial: 26769016
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL 7% hypertonic saline
Trial: 17122083
Drug: Rosi (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosi (8 mg/d)
Trial: 17122083
Drug: Rosi (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosi (20 mg/kg·d)
Trial: 17122083
Drug: Rosi treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosi treatment (1 μM)
Trial: 12856053
Drug: Four weeks
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four weeks of aminosidine (paromomycin) ointment
Trial: 12856053
Drug: Two weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two weeks of aminosidine (paromomycin) ointment and two weeks of placebo